The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his ...
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources ...
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over ...
The mission of the Industrial Partnership team is to detect, promote, assist and protect the inventive activities from research (inventions, know-how and biological materials) conducted at the Institut Pasteur (and in some Institutes of its international network), and transfer there to industrial ...
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study ...
Carriers of a genetic mutation show increased dependence on tobacco
Scientists at the Institut Pasteur, the French National Center for Scientific Research (CNRS) and Pierre and Marie Curie University (UPMC) have recently proven that, in mice, nicotine intake – nicotine is the main addictive substance in tobacco – is heavily regulated by a genetic mutation that is very common in humans.
Clinical trial launched to treat Sanfilippo B syndrome using gene therapy
A phase I/II gene therapy clinical trial for children suffering from Sanfilippo B syndrome, a rare genetic disease, enrolled a first patient in October of this year. The trial is being carried out and coordinated by the Institut Pasteur (the trial’s sponsor), Inserm, AFM-Téléthon and Vaincre les Maladies Lysosomales (VML). It is being conducted at Bicêtre Hospital (AP-HP) in Paris. If the treatment is successful it will pave the way towards the development of other gene therapy treatments using the same process.
Two European programs reinforce the fight against emerging diseases
The 31 partners involved in the two major European research programs PREDEMICS and ANTIGONE are to meet for a joint seminar at the Institut Pasteur on November 6th. These two programs will respectively receive €11.7 million and €12 million funding of the European Union over five years to study the emergence mechanisms of infectious diseases in order to strengthen existing treatment and prevention. Since their launch, PREDEMICS and ANTIGONE have been active in various areas, in particular for modeling the spread and evolution of emerging pathogens and for studying host-pathogen interactions.
Identification of a new mechanism in immunotherapy for lymphoma
Using innovative dynamic imaging technique, scientists at the Institut Pasteur, Inserm and the VU Medical Center in Amsterdam have uncovered the mode of action of anti-CD20, an antibody therapy frequently used in the treatment of lymphomas (cancers of the immune system) as well as some auto-immune diseases. In a lymphoma model, the scientists have been able to carry out real time in vivo imaging of the cellular events activated by the treatment and resulting in the destruction of tumor cells. These discoveries should help optimize the efficacy of future therapies involving anti-CD20 antibodies. This work is the subject of an article published online November 1 on the Journal of Clinical Investigation website.
Fine-tuning the approach to malaria and toxoplasmosis research
A study carried out by teams from the Institut Pasteur, the Institut Cochin (Inserm, CNRS, Paris Descartes University), and the Wellcome Trust Centre for Molecular Parasitology at the University of Glasgow, may very well redefine current approaches to malaria and toxoplasmosis research in terms of treatment development. Their research which focuses on the role played by the protein AMA1 (present in both parasites) was published october 9, on the Nature Communications website. For many years AMA1 has been the focus of studies aiming to develop malaria treatments and vaccines. However, the authors of this study express their reservations about strategies that focus strictly on blocking AMA1 and show that malaria and toxoplasmosis parasites without AMA1 are still capable of developing normally.
Potential therapeutic targets for blocking AIDS virus replication
Scientists from the Institut Pasteur and Inserm have identified several proteins in humans as potential new therapeutic targets for treating the AIDS virus. These proteins are part of a complex cellular mechanism that blocks the virus replication in cells called macrophages. The discovery of this mechanism and the proteins involved gives scientists a solid theoretical basis for developing new therapeutic strategies to be used alongside anti-retroviral treatments currently in use. This research was published online September 30, 2013 by the scientific journal Proceedings of the National Academy of Sciences.
Dengue: identifying mosquito genetic factors that control virus transmission
Dengue is currently the most common insect-borne viral disease of humans worldwide. Scientists from the Institut Pasteur, the French National Center for Scientific Research (CNRS), and the Armed Forces Research Institute of Medical Sciences (AFRIMS) have discovered several genetic factors controlling the transmission of various dengue virus strains in a natural population of mosquitoes in Thailand. Their results indicate that the transmission of these viruses in nature depends not only on mosquito genetic factors but also on their specific interaction with viral genetic factors. This discovery significantly advances our understanding of dengue biology in nature. From a more general standpoint, this study also refines our view of the genetic basis of host-pathogen interactions. This work was published August 1st, 2013 on the PLoS Genetics website.
Retracing the evolutionary history and emergence of tuberculosis
In association with CEA-Genoscope and the Sanger Institute, scientists at the Institut Pasteur in Paris, the CNRS, INSERM, the Institut Pasteur of Lille, and Université Lille 2 have recently determined the origin of the emergence of the Mycobacterium tuberculosis bacterium, the main causative agent of tuberculosis. Researchers have also provided insights into its evolutionary success. They have identified several genetic mechanisms that could have contributed to the worldwide dissemination of this pathogen, which currently infects up to 2 billion people. This research, published on the Nature Genetics website on January 6, offers possibilities for identifying new targets in the fight against tuberculosis.